These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38957120)

  • 21. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
    Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer.
    Hu D; Qian J; Yin F; Wei B; Wang J; Zhang H; Yang H
    Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():170-175. PubMed ID: 38663180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
    Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
    O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
    Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing early detection programs for ovarian cancer.
    Urban N
    Ann Oncol; 2011 Dec; 22 Suppl 8(Suppl 8):viii6-viii18. PubMed ID: 22180403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
    Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.
    Langmár Z; Németh M; Vleskó G; Király M; Hornyák L; Bösze P
    Eur J Gynaecol Oncol; 2011; 32(6):605-10. PubMed ID: 22335019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
    Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
    BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A
    Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    Haque R; Skates SJ; Armstrong MA; Lentz SE; Anderson M; Jiang W; Alvarado MM; Chillemi G; Shaw SF; Kushi LH; Powell CB
    Gynecol Oncol; 2020 May; 157(2):521-528. PubMed ID: 32145911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer.
    Qiao L; Chen X; Xi X; Chen X; Zhang P; Dong H; Wu X; Chen X
    Medicine (Baltimore); 2020 Dec; 99(49):e23329. PubMed ID: 33285710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
    Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
    BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer.
    Granato T; Midulla C; Longo F; Colaprisca B; Frati L; Anastasi E
    Tumour Biol; 2012 Oct; 33(5):1335-9. PubMed ID: 22528938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
    Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
    Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
    Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.